

Attorney Docket No.: PENN-0789
Inventors: Siegel et al.
Serial No.: 10/046,504
Filing Date: October 19, 2001
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1: (currently amended) A surgically implantable drug delivery system for delivery of steady state concentrations of haloperidol to a patient for 5 months or more consisting essentially of a biodegradable polymer or copolymer and haloperidol fabricated into an implant via solvent casting and compression molding at a temperature and pressure which allows the haloperidol-polymer material to flow into a mold for an implant which is surgically implanted underneath the skin of a patient and is removable from the patient in the event the patient exhibits unwanted side effects following implantation.

Claim 2: (original) The surgically implantable drug delivery system of claim 1 wherein the biodegradable polymer comprises polylactide or a lactide-co-glycolide copolymer.

Claim 3: (original) The surgically implantable drug delivery system of claim 1 comprising 50 to 100% polylactide and 0 to 50% polyglycolide.

Claim 4: (currently amended) A method of producing an implant which is surgically implanted underneath the skin of

Attorney Docket No.: PENN-0789
Inventors: Siegel et al.
Serial No.: 10/046,504
Filing Date: October 19, 2001
Page 4

a patient for delivery of steady state concentrations of haloperidol to the patient for five months or more comprising:

- (a) dissolving haloperidol and a biodegradable polymer in acetone;
- (b) solvent casting the haloperidol and biodegradable polymer solution to produce a completely dry haloperidol-polymer material; and
- (c) molding under compression the dry haloperidol-polymer material into at a temperature and pressure which allows the haloperidol-polymer material to flow into a mold for an implant which is surgically implanted underneath the skin of a patient and is removable following implantation into a patient in the event the patient exhibits unwanted side effects following implantation.

Claim 5: (original) The method of claim 4 wherein the biodegradable polymer comprises polylactide or a lactide-co-glycolide copolymer.

Claim 6: (original) The method of claim 4 wherein the biodegradable polymer comprises 50 to 100% polylactide and 0 to 50% polyglycolide.

Attorney Docket No.: PENN-0789
Inventors: Siegel et al.
Serial No.: 10/046,504
Filing Date: October 19, 2001
Page 5

Claim 7: (original) A method for treating patients with psychotic conditions and diseases comprising surgically implanting into a patient suffering from a psychotic condition or disease the surgically implantable drug delivery system of claim 1.

Claim 8: (original) The method of claim 7 wherein the surgically implantable drug delivery system is implanted under the skin of a patient between the muscle and dermis.

Claim 9: (original) The method of claim 7 wherein the patient is suffering from schizophrenia.

Claim 10: (original) The method of claim 7 further comprising administering to the patient an antipsychotic drug orally.